biostudies-literatureUnknown67(1)Burdette DGilead SciencesThe standard of care for the treatment of chronic hepatitis B (CHB) is typically lifelong treatment with nucleos(t)ide analogs (NAs), which suppress viral replication and provide long-term clinical benefits. However, infectious virus can still be detected in patients who are virally suppressed on NA therapy, which may contribute to the failure of these agents to cure most CHB patients. Accordingly, new antiviral treatment options are being developed to enhance the suppression of hepatitis B virus (HBV) replication in combination with NAs ("antiviral intensification"). Here, we describe GS-SBA-1, a capsid assembly modulator (CAM) belonging to class CAM-E, that demonstrates potent inhibition of extracellular HBV DNA <i>in vitro</i> (EC₅₀ [50% effective concentration] = 19 nM) in HAntimicrobial agents and chemotherapye0134822https://www.ebi.ac.uk/biostudies/studies/S-EPMC9872672biostudies-literatureCharacterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.PMC9872672Niu CYue QKobayashi TFletcher SPMedley JBeran RKTam DMorganelli PLazerwith SNovikov NFeierbach BLi LWang JNiedziela-Majka ALiu YTang JBurdette DHyrina ACheung TGilmore SDelaney WEMehra UHoldorf MMSong ZfalseCharacterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection.The standard of care for the treatment of chronic hepatitis B (CHB) is typically lifelong treatment with nucleos(t)ide analogs (NAs), which suppress viral replication and provide long-term clinical benefits. However, infectious virus can still be detected in patients who are virally suppressed on NA therapy, which may contribute to the failure of these agents to cure most CHB patients. Accordingly, new antiviral treatment options are being developed to enhance the suppression of hepatitis B virus (HBV) replication in combination with NAs ("antiviral intensification"). Here, we describe GS-SBA-1, a capsid assembly modulator (CAM) belonging to class CAM-E, that demonstrates potent inhibition of extracellular HBV DNA <i>in vitro</i> (EC₅₀ [50% effective concentration] = 19 nM) in H2023-01-01T00:00:00Z2023 Jan2026-07-14T17:17:28.799Z2026-06-21T03:12:36.205ZS-EPMC98726723651989210.1128/aac.01348-22